Leadership Overview
Synexus has 4 executives leading key functions including strategy, financial oversight, and operational execution.
Driven by a commitment to advancing clinical research, Synexus provides essential site and patient services, focusing on efficient trial planning and patient enrollment to accelerate medical breakthroughs globally.
Driven by a commitment to advancing clinical research, Synexus provides essential site and patient services, focusing on efficient trial planning and patient enrollment to accelerate medical breakthroughs globally.
Leadership Roles at Synexus
Lucia Smigel - Chief Executive Officer
Lucia Smigel, the Chief Executive Officer at Synexus, directs the overarching corporate strategy and operational framework. Overseeing global site and patient services, Smigel ensures the efficient execution of clinical trial planning and patient enrollment initiatives. This leadership role involves driving innovation in service delivery to accelerate medical research timelines. By optimizing resource allocation and fostering cross-functional collaboration, Lucia Smigel directly impacts the company's ability to meet client demands and expand market reach. The focus remains on enhancing the quality and speed of clinical trial processes, solidifying Synexus's position as a leader in the research support sector.
O.P.Y. Liang - Group Chief Executive Officer
O.P.Y. Liang, the Group Chief Executive Officer at Synexus, spearheads the strategic direction and expansion of the organization across its global operations. Liang's purview encompasses the integration of site and patient services, ensuring seamless trial planning and patient enrollment processes worldwide. This executive function involves cultivating strategic partnerships and identifying new market opportunities to enhance Synexus's international presence. By driving operational excellence and fostering a culture of continuous improvement, O.P.Y. Liang significantly contributes to the company's growth trajectory. The objective is to elevate Synexus's capabilities in supporting complex clinical trials, thereby advancing global health outcomes.
Tyler Hagl - Founder & Chief Executive Officer
Tyler Hagl, the Founder & Chief Executive Officer at Synexus, established the company's foundational mission and continues to guide its strategic vision. Hagl's leadership focuses on the core services of site and patient support for clinical trials, emphasizing patient enrollment and global coverage. This role involves setting the standard for operational efficiency and innovation within the research services sector. By championing the company's commitment to accelerating medical discoveries, Tyler Hagl ensures Synexus remains at the forefront of clinical trial support. The founder's ongoing influence drives the organization's dedication to providing comprehensive solutions that benefit both researchers and patients.
Craig Smith - Chief Financial Officer
Craig Smith, the Chief Financial Officer at Synexus, manages the company's financial health and strategic fiscal planning. Smith oversees all financial operations, including budgeting, forecasting, and resource allocation for site and patient services. This critical function ensures the financial viability and sustainable growth of Synexus's global trial planning and patient enrollment initiatives. By implementing robust financial controls and driving cost-efficiency measures, Craig Smith directly supports the company's mission to accelerate clinical research. The CFO's expertise is vital in navigating the financial complexities of the biopharmaceutical services industry and maximizing shareholder value.
Explore Leadership Teams in Business Services
NCI is attempting to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers.
Company Leadership SJ
DK
GT
AL
Founded in 1984, the Jefferson Lab is headquartered in Newport News, Virginia. They conduct basic research of the atom's nucleus using the lab's unique particle accelerator, known as the Continuous Electron Beam Accelerator Facility (CEBAF).
Company Leadership GF
BB
JH
Lloyd's Register Group Limited (LR) is a technical and professional services organisation and a maritime classification society, wholly owned by the Lloyds Register Foundation, a UK charity dedicated to research and education in science and engineering. The organisation dates to 1760. Its stated aims are to enhance the safety of life, property, and the environment, by helping its clients (including by validation, certification, and accreditation) to improve the safety and performance of complex projects, supply chains and critical infrastructure. In July 2012, the organisation converted from an industrial and provident society to a company limited by shares, named Lloyds Register Group Limited, with the new Lloyds Register Foundation as the sole shareholder. At the same time the organisation gave to the Foundation a substantial bond and equity portfolio to assist it with its charitable purposes. It will benefit from continued funding from the groups operating arm, Lloyds Register Group Limited. In 2020, Lloyd's Register sold its Energy business Lloyd's Register is unaffiliated with Lloyd's of London, but emerged from the same professional and social circles that historically met at Lloyd's Coffee House, from which both organisations took their name.
Company Leadership ST
SP
JH
DC
Founded in 1964, DHI is a company that specializes in water management protecting against oil spills, flood protection and water quality. DHI is headquartered in Vietnam.
Company Leadership LP
RT
CH
Frequently Asked Questions Regarding Synexus Top Executives and Leadership Team
